top of page

HoneyNaps initiates clinical trials for digital therapeutics for insomnia

Reported by Business Korea / Jan 04, 2023

HoneyNaps announced that on October 12th, they commenced clinical trials for the study titled "Sleep index-based treatment of insomnia: Evaluating efficacy and safety of digital therapeutics for insomnia" in collaboration with Professor Seokhoon Jeong's team at Seoul Asan Hospital.

Professor Seokhoon Jeong from Seoul Asan Hospital, who is conducting the collaborative clinical research, is a leading authority in the field of Cognitive Behavioral Therapy for Insomnia (CBT-i). The development of an effective treatment for insomnia is highly anticipated.

The clinical trial representative from HoneyNaps stated, "In addition to our expertise in sleep biosignal sensing and sleep disorder diagnostics, HoneyNaps has been focusing on securing technology for digital therapeutics for insomnia since 2020. Through this effort, we aim to become the world's first company with an integrated solution pipeline for the management and treatment of sleep disorders. Our product, SOMNUM Medella (DTx), is scheduled to complete clinical and data analysis work by the first half of 2023. We have also initiated discussions for domestic validation clinical trials (IDE, Investigational Device Exemption) and clinical verification with leading universities in the United States to obtain the first FDA approval in South Korea."


bottom of page